Abstract
Dengue virus type 2 from infected human serum has been adapted to DBS-FRhL-2 and WI-38 cells which are candidate substrates for virus vaccine production. Initially, the infected DBS-FRhL-2 monolayers were refed with maintenance medium and were reharvested after prolonged incubation. With WI-38 cells, virus could be recovered only if previously passaged in DBS-FRhL-2 or primary African Green monkey kidney cells. Peak titers of 106 per 0·2 ml were obtained with DBS-FRhL-2 cells whereas maximum titers of 105 per 0·2 ml were obtained with WI-38 cells. After six passages in the two cell strains there appeared to be no attenuation of the virus in terms of mouse neurovirulence.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
